Omnicell (NASDAQ:OMCL) Downgraded by Zacks Research to Hold

Zacks Research downgraded shares of Omnicell (NASDAQ:OMCL) from a strong-buy rating to a hold rating in a research note released on Tuesday morning,Zacks.com reports.

A number of other analysts have also recently commented on the company. Wall Street Zen raised Omnicell from a “buy” rating to a “strong-buy” rating in a research report on Sunday, May 10th. UBS Group set a $60.00 target price on Omnicell and gave the stock a “buy” rating in a research note on Friday, March 13th. Craig Hallum restated a “buy” rating and set a $55.00 price target on shares of Omnicell in a report on Wednesday, April 29th. Wells Fargo & Company lifted their price target on Omnicell from $52.00 to $55.00 and gave the stock an “overweight” rating in a research report on Thursday, April 23rd. Finally, Weiss Ratings upgraded shares of Omnicell from a “sell (d)” rating to a “hold (c-)” rating in a research note on Thursday, May 7th. Seven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $59.86.

Omnicell Trading Up 1.7%

Shares of OMCL opened at $45.12 on Tuesday. The stock has a market capitalization of $2.05 billion, a P/E ratio of 102.55, a PEG ratio of 1.15 and a beta of 0.96. Omnicell has a twelve month low of $26.84 and a twelve month high of $55.00. The company has a quick ratio of 1.29, a current ratio of 1.50 and a debt-to-equity ratio of 0.13. The firm has a fifty day simple moving average of $42.20 and a two-hundred day simple moving average of $41.50.

Omnicell (NASDAQ:OMCL) last posted its earnings results on Tuesday, April 28th. The company reported $0.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.33 by $0.22. Omnicell had a return on equity of 4.00% and a net margin of 1.67%.The firm had revenue of $309.88 million for the quarter, compared to analysts’ expectations of $304.02 million. During the same period in the previous year, the firm earned $0.26 earnings per share. The business’s revenue was up 14.9% compared to the same quarter last year. Omnicell has set its FY 2026 guidance at 1.800-2.000 EPS and its Q2 2026 guidance at 0.400-48.000 EPS. On average, research analysts anticipate that Omnicell will post 1.31 EPS for the current year.

Insiders Place Their Bets

In related news, EVP Nnamdi Njoku sold 3,090 shares of the firm’s stock in a transaction on Monday, May 18th. The shares were sold at an average price of $43.22, for a total value of $133,549.80. Following the completion of the transaction, the executive vice president directly owned 154,785 shares of the company’s stock, valued at approximately $6,689,807.70. This trade represents a 1.96% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Corey J. Manley sold 5,025 shares of the business’s stock in a transaction dated Monday, May 18th. The stock was sold at an average price of $43.22, for a total transaction of $217,180.50. Following the completion of the sale, the executive vice president owned 112,783 shares in the company, valued at approximately $4,874,481.26. This trade represents a 4.27% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 2.92% of the company’s stock.

Institutional Trading of Omnicell

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Wellington Management Group LLP lifted its position in Omnicell by 156.4% in the fourth quarter. Wellington Management Group LLP now owns 2,075,362 shares of the company’s stock worth $94,014,000 after buying an additional 1,265,818 shares during the last quarter. Millennium Management LLC bought a new position in Omnicell during the third quarter valued at $25,625,000. First Light Asset Management LLC purchased a new stake in shares of Omnicell in the first quarter valued at $16,351,000. Boston Partners purchased a new stake in shares of Omnicell in the fourth quarter valued at $20,805,000. Finally, WCM Investment Management LLC bought a new stake in shares of Omnicell in the 1st quarter worth about $9,783,000. Hedge funds and other institutional investors own 97.70% of the company’s stock.

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.